Shaw Leaves Lilly To Helm Gilead’s Kite

After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.

Christi Shaw
Christi Shaw led Lilly Bio-Medicines since January 2017

Investors were caught by surprise on 11 July as Eli Lilly & Co. revealed that the president of its Bio-Medicines unit, Christi Shaw, is leaving at the end of August, with Patrick Jonsson, currently president and general manager of Lilly Japan, selected to succeed her. Shaw’s move wasn’t a mystery for long.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business